# A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

> **NCT07105488** · PHASE2 · RECRUITING · sponsor: **Bluefin Biomedicine, Inc.** · enrollment: 225 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **BIOLOGICAL:** BFB759
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07105488
- **Lead sponsor:** Bluefin Biomedicine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-03-31
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105488, "A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07105488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*